News from Gilead Sciences
Stay current with all the latest and breaking news about Gilead Sciences, compare headlines and perspectives between news sources on stories happening today. In total, 15 stories have been published about Gilead Sciences which Ground News has aggregated in the past 3 months.
Covered Most By
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Gilead Sciences News
Latest News Stories
Gilead Sciences · MarylandGilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026. Gilead paid nearly $12 billion in 2017 to buy Kite, one of the leading players in the emerging field of CAR-T therapies. The company has been working for several years to build its presence in oncology.See the Story
Gilead CAR-T cancer therapy capacity to quadruple by 2026
100% Center coverage: 1 sources
Gilead Sciences · Foster CityGilead Sciences Inc (NASDAQ:GILD) said it paused tumor study enrollment. The Food and Drug Administration (FDA) subsequently requested a partial clinical hold on these trials. Gilead is reviewing the benefit-risk of magrolimab across all ongoing trials and will provide an update on this assessment as soon as possible. Patients already enrolled in the Gilead-sponsored ELEVATE solid tumor studies and deriving clinical benefit may continue to choo…See the Story
Why Is Gilead Sciences Stock Trading Lower Today? - Gilead Sciences (NASDAQ:GILD)
100% Center coverage: 1 sources
Gilead Sciences · United StatesGilead is reviewing the benefit-risk of magrolimab across all ongoing trials. The drug is an antibody treatment that blocks a type of protein, called CD47. Gilead gained access to the treatment through its $4.9 billion purchase of Forty Seven Inc in 2020.See the Story
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
100% Center coverage: 1 sources
FAGilead Sciences (NASDAQ:GILD) has agreed to acquire CymaBay Therapeutics (NASdaq:CBAY) for a total equity value of $4.3B. The deal is expected to close during the first quarter of 2024, subject to regulatory approvals and other customary closing conditions.See the Story
Why Is CymaBay Therapeutics Stock Trading Higher Today? - CymaBay Therapeutics (NASDAQ:CBAY), Gilead Sciences (NASDAQ:GILD)
Coverage: 2 sources
Gilead Sciences · ElkaderGilead Sciences, a leading biotechnology company, has reported its full year 2023 financial results, indicating a flat revenue of US$27.1b compared to the previous year. Despite this, the company experienced a significant increase in net income, reaching US$5.67b, reflecting a 23% growth from the previous year. The company’s profit margin also demonstrated improvement, rising from 17% in FY 2022 to 21% in FY 2023. This positive shift contributed…See the Story
Gilead Sciences Shows Resilience with Flat Revenue and Increased Profit Margin in Full Year 2023 Results
100% Center coverage: 1 sources
